MedPath

Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer

Phase 3
Suspended
Conditions
Ovarian Cancer
Registration Number
NCT01218490
Lead Sponsor
Institut Cancerologie de l'Ouest
Brief Summary

It is a multicenter randomized trial of superior cleaning compared the absence of dissection in stage III patients with optimal surgical resection without retroperitoneal lymph node palpable.

Detailed Description

Not available

Recruitment & Eligibility

Status
SUSPENDED
Sex
Female
Target Recruitment
450
Inclusion Criteria
  • Age> 18 years
  • Karnofsky> 80, or ASA I-II
  • Primary ovarian adenocarcinoma, or primitive peritoneal
  • No retroperitoneal lymph node> 2cm (CT; MRI)
  • Complete surgical staging
  • Stage III-IV FIGO classification
  • Indication of systemic chemotherapy before surgery or post surgery
Exclusion Criteria
  • Non Invasive Cancer
  • non-epithelial or borderline cancer
  • Pregnancy
  • Previous pelvic lymphadenectomy or aortic-cava for a disease other than ovarian cancer
  • Contraindication to Platinum and Paclitaxel
  • Borderline Ovarian Tumor
  • tumor recurrence
  • Incomplete surgery, resectable lesion, Surgery sub optimal (R> 1cm)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
survival with out recurrence5 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (17)

Clinique Sainte Thérèse

🇫🇷

Amiens, France

Centre Paul Papin

🇫🇷

Angers, France

Hospital

🇫🇷

Lyon, France

Centre Jean Perrin

🇫🇷

Clermont-Ferrand, France

Centre G F Leclerc

🇫🇷

Dijon, France

Institut Paoli Calmette

🇫🇷

Marseille, France

Centre Val d'Aurelle

🇫🇷

Montpellier, France

Hôpital Européen Georges Pompidou

🇫🇷

Paris, France

Hôpital Lariboisière

🇫🇷

Paris, France

Hôpital des Diaconesses

🇫🇷

Paris, France

Scroll for more (7 remaining)
Clinique Sainte Thérèse
🇫🇷Amiens, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.